NeuroPace (NPCE) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Greetings, and welcome to the NeuroPace First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce Jeremy Feffer of LifeSci Advisors. Please go ahead. Speaker1 Good afternoon. Thank you for joining us for Neuropace's first quarte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40337 NEUROPACE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organi ...

This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking s ...

NeuroPace Reports First Quarter 2025 Financial Results Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products Increased full-year 2025 revenue guidance to $93 to $97 million On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025 Management scheduled to host a conference call today at 4:30 p.m. ET The Company's cash, cash equivalents and short-term investments balance as of March 31, 2025, was $66.3 ...

-- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025 -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transformin ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

-- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on its exposure to tariffs that have been implemented. While specific policies and timing of implementation remain fluid, NeuroPace expects minimal impact to its o ...

Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1Long-term seizure reduction with a median reduction of 82% at 3 years.Seizure freedom with 42% of patients remaining seizure free for 6+ months.i MOUNTAIN VIEW, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced three-year effectiveness dat ...

文章核心观点 NeuroPace公司将参加2025年美国神经病学学会（AAN）年会并展示RNS系统治疗耐药性局灶性癫痫（DRE）的相关数据，致力于帮助DRE患者 [1][2] 公司信息 - 公司是位于加州山景城的商业阶段医疗设备公司，专注改善癫痫患者生活，其RNS系统可在癫痫发作源提供个性化实时治疗 [5] 会议信息 会议时间地点 - 2025年4月5 - 9日在圣地亚哥举行 [1] 公司活动 - 4月7日周一下午5:06 - 5:18 PDT在SDCC 29A室，由Dawn Eliashiv医生进行RNS系统多中心批准后研究的口头报告 [7] - 4月8日周二下午12:00 - 12:20 PDT在展位展示区2100过道，由Martha Morrell医生和Barbara Jobst医生进行报告 [7] - 无法亲临会议的临床医生可参加4月8日周二上午8:00 PDT和4月11日周五下午12:00 PDT的网络研讨会，由Martha Morrell医生和Dawn Eliashiv医生进行报告 [7] - RNS系统将在1642号展位展示，还会在展位展示区舞台进行PAS研究展示 [2][3] 联系方式 - 市场副总裁Katie Keller，邮箱kkeller@neuropace.com [9] - 投资者联系Jeremy Feffer，邮箱jfeffer@lifesciadvisors.com [9] 更多信息获取途径 - 可前往2025 AAN年会1642号展位或访问https://www.neuropace.com [4]

文章核心观点 公司为战略聚焦核心RNS系统产品线，将终止SEEG产品分销关系，维持2025年营收指引和长期计划预期，预计2026年有显著增长机会 [1][3][6] 分组1：战略调整 - 公司将终止SEEG产品分销关系，2025年第四季度开始逐步结束，持续至2026年第一季度 [1] - 公司核心增长战略已显著演变，2026年起商业团队将聚焦RNS系统相关机会 [2] 分组2：公司概况 - 公司位于加州山景城，致力于改善癫痫患者生活，其RNS系统是首个且唯一商用的脑响应平台 [5] 分组3：财务与业务预期 - 考虑分销协议到期和库存销售时间，公司维持2025年营收指引 [6] - 因SEEG产品毛利率约50%，RNS系统毛利率超78%，公司毛利率有望提升 [6] - 2026年公司有显著增长机会，包括Project CARE持续扩张、适应症拓展和AI软件产品推出 [6] - 公司认为SEEG市场有多家竞品，客户将得到良好支持 [6]